Benitec Biopharma Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Benitec Biopharma Inc. (BNTC) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 3.96% for the 12-month period ending 2023-06-30, per its 10-K filed 2023-09-21.
Discontinued › Notes › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2023-09-21
- Benitec Biopharma Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2023 was 3.96%, a 191.18% increase from fiscal 2022.
- Benitec Biopharma Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2022 was 1.36%, a 209.09% increase from fiscal 2021.
- Benitec Biopharma Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2021 was 0.44%, a 65.63% decline from fiscal 2020.
- Benitec Biopharma Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2020 was 1.28%, a 0.00% change from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month |
|---|---|
| 2023-06-30 | 3.96% 10-K · filed 2023-09-21 |
| 2022-06-30 | 1.36% 10-K · filed 2023-09-21 |
| 2021-06-30 | 0.44% 10-K · filed 2022-09-02 |
| 2020-06-30 | 1.28% 10-K · filed 2021-09-20 |
| 2019-06-30 | 1.28% 10-K · filed 2020-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |